 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | pramlintide/insulin A21G (ADO09) / Adocia
Journal: A co-formulation of pramlintide and insulin A21G (ADO09) improves post-prandial glucose and short-term control of mean glucose, time in range, and body weight versus insulin aspart in adults with type 1 diabetes. (Pubmed Central) - Apr 4, 2023
In comparison with aspart, ADO09 was well tolerated and effective in T1D across a wide range of dosage, significantly improving the average blood glucose level and body weight during 24?days of ambulatory treatment. Meal test profiles confirmed improvement of glycaemic patterns and other responses with ADO09.
- pramlintide/insulin A21G (ADO09) / Adocia
Ado09, a co-formulation of pramlintide and insulin A21G, improves body weight and treatment satisfaction compared to insulin lispro in people with type 1 diabetes (PwT1D) (Short Oral Discussion Area) - Jul 9, 2022 - Abstract #EASD2022EASD_660;
P2
Materials and During a run-in period of 2-4 weeks, basal insulin was switched to insulin degludec or glargine and continuous glucose monitoring (CGM) initiated... In this 4 months treatment study in PwT1D, ADO09 showed similar overall effects on glycaemic control and hypoglycaemia to LIS, but significantly lowered body weight and improved treatment satisfaction.
- ||| pramlintide/insulin A21G (ADO09) / Adocia
Trial completion: A Trial to Assess the Efficacy and Safety of M1 Pram P037 Prandial Insulin in Subjects With Type 1 Diabetes (T1DM) (clinicaltrials.gov) - Jun 24, 2022
P2, N=80, Completed, Sponsor: Adocia
In this 4 months treatment study in PwT1D, ADO09 showed similar overall effects on glycaemic control and hypoglycaemia to LIS, but significantly lowered body weight and improved treatment satisfaction. Recruiting --> Completed
- Tresiba (insulin degludec) / Novo Nordisk
[VIRTUAL] Ado09, a co-formulation of pramlintide and insulin A21G improves post-prandial glucose and body weight versus insulin aspart in type 1 diabetes (Barcelona Hall) - Jul 13, 2021 - Abstract #EASD2021EASD_1309;
P1/2
Part A was conducted in participants using less than 40 U prandial insulin per day, part B in subjects using 40 to 75 U prandial insulin per day.Materials and During a 28 days run-in period, basal insulin was switched to insulin degludec and titrated... ADO09 was well tolerated and significantly improved post-prandial blood glucose control, hyperglucagonemia, CGM-metrics and body weight versus insulin aspart over 24 days across a wide range of prandial insulin doses.
- | pramlintide/insulin A21G (ADO09) / Adocia
Journal: ADO09, a co-formulation of the amylin-analog pramlintide and the insulin analog A21G, lowers postprandial blood glucose versus insulin lispro in type 1 diabetes (T1D). (Pubmed Central) - Jul 11, 2021
ADO09 formulation was generally similar to the separate administration of insulin and pramlintide, except a better blood glucose level in the 4-8h interval postmeal. These positive results warrant further investigations with ADO09.
- |||| pramlintide/insulin A21G (ADO09) / Adocia
New P2 trial: A Trial to Assess the Efficacy and Safety of M1 Pram P037 Prandial Insulin in Subjects With Type 1 Diabetes (T1DM) (clinicaltrials.gov) - Mar 24, 2021
P2, N=80, Recruiting, Sponsor: Adocia
- || pramlintide/insulin A21G (ADO09) / Adocia
Trial completion: A Trial to Assess Safety and Efficacy of ADO09 Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus (clinicaltrials.gov) - Nov 30, 2020
P1/2, N=44, Completed, Sponsor: Adocia
These positive results warrant further investigations with ADO09. Recruiting --> Completed
- ||| pramlintide/insulin A21G (ADO09) / Adocia
Enrollment change, Trial completion date, Trial primary completion date: A Trial to Assess Safety and Efficacy of ADO09 Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus (clinicaltrials.gov) - Apr 27, 2020
P1/2, N=40, Recruiting, Sponsor: Adocia
Recruiting --> Completed N=24 --> 40 | Trial completion date: Nov 2019 --> Sep 2020 | Trial primary completion date: Nov 2019 --> Jul 2020
- || pramlintide/insulin A21G (ADO09) / Adocia
New P1/2 trial: A Trial to Assess Safety and Efficacy of ADO09 Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus (clinicaltrials.gov) - Jun 11, 2019
P1/2, N=24, Recruiting, Sponsor: Adocia
- || pramlintide/insulin A21G (ADO09) / Adocia
New P1 trial: A Trial to Assess a Co-formulation of an Insulin Analog and Pramlintide in Subjects With Type 1 Diabetes Mellitus (clinicaltrials.gov) - Apr 15, 2019
P1, N=24, Completed, Sponsor: Adocia